<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00868426</url>
  </required_header>
  <id_info>
    <org_study_id>3103001</org_study_id>
    <nct_id>NCT00868426</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Pilot Study on Budesonide/Formoterol Device-metered Dry Powder Inhaler</brief_title>
  <official_title>Pharmacokinetic Pilot Study on Budesonide/Formoterol Device-metered Dry Powder Inhaler, Symbicort Turbuhaler; an Open, Single Center, Single Dose Study With 3-way Crossover Design in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orion Corporation, Orion Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this pilot study is to assess the methodology, practical arrangements and
      pulmonary absorption with charcoal blockage for the future bioequivalence studies. In
      addition, PK of budesonide and formoterol after administration from 2 different batches of
      Symbicort TH is compared with each other.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the methodology, practical arrangements and pulmonary absorption with charcoal blockage</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of budesonide and formoterol after administration of two different batches of Symbicort Turbuhaler</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Budesonide/Formoterol Batch 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Budesonide/Formoterol Batch 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Budesonide/Formoterol Batch 1 and charcoal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide/Formoterol Batch 1</intervention_name>
    <description>Single, inhaled dose</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Symbicort Turbuhaler</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide/Formoterol Batch 2</intervention_name>
    <description>Single, inhaled dose</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Symbicort Turbuhaler</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide/Formoterol Batch 1 and charcoal</intervention_name>
    <description>Single, inhaled dose</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Symbicort Turbuhaler</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Good general health ascertained by detailed medical history, and laboratory and
             physical examinations

          -  Finnish speaking males and females, 18-55 (inclusive) years of age

          -  Normal weight defined as body mass index (BMI) &gt; 19 and &lt; 30 kg/m2

          -  Weight at least 50 kg

          -  Regular intestinal transit

        Exclusion Criteria:

          -  Evidence of a clinically significant cardiovascular, renal, hepatic, haematological,
             gastrointestinal, pulmonary, metabolic-endocrine, neurological or psychiatric disease

          -  Any abnormal value of laboratory, vital signs, 12-lead electrocardiogram or physical
             exam which may in the opinion of the investigator interfere with the test results or
             cause a health risk for the subject if he/she takes part into the study

          -  Any condition requiring regular concomitant treatment (including vitamins and herbal
             products) or likely to need any concomitant treatment during the study

          -  Known hypersensitivity to the active substance(s) or to any of the excipients of the
             drug

          -  Pregnant or lactating females

          -  Recent or current (suspected) drug abuse or positive result in the drugs abuse test

          -  Recent or current alcohol abuse (regular drinking more than 21 units per week for
             males and more than 16 units per week for females [1 unit = 4 cl spirits or
             equivalent])

          -  Current use of nicotine containing products more than 5 cigarettes (or equivalent)/day
             and/or inability to refrain from the use of nicotine containing products during the
             study

          -  Use of caffeine containing beverages more than 600 mg of caffeine/day and/or inability
             to refrain from the use of caffeine containing beverages during the treatment periods
             until 24 h after study treatment administration

          -  Blood donation or loss of significant amount of blood within 90 days prior to the
             first study treatment administration

          -  Administration of another investigational drug within 90 days prior to the first study
             treatment administration

          -  Unsuitable veins for repeated venipuncture or for cannulation

          -  Inability to learn the correct inhalation technique

          -  Inability to participate in all treatment periods
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kimmo Ingman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orion Corporation, Orion Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orion Pharma Phase I Unit</name>
      <address>
        <city>Espoo</city>
        <zip>02101</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2009</study_first_submitted>
  <study_first_submitted_qc>March 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2009</study_first_posted>
  <last_update_submitted>August 12, 2009</last_update_submitted>
  <last_update_submitted_qc>August 12, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2009</last_update_posted>
  <responsible_party>
    <name_title>Ulla Sairanen, Clinical study director</name_title>
    <organization>Orion Corporation, Orion Pharma</organization>
  </responsible_party>
  <keyword>Healthy volunteer study</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
    <mesh_term>Charcoal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

